ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

Core Insights - AngioDynamics, Inc. (ANGO) announced that its Irreversible Electroporation (IRE) technology has received Current Procedural Terminology (CPT) Category I codes for treating lesions in the prostate and liver, indicating clinical efficacy and value in the medical community [1][2] - Following the announcement, ANGO's stock price increased by nearly 11.2% to $7.27, although the stock has declined 7.3% year-to-date compared to an 8.4% rise in the industry and a 22.7% increase in the S&P 500 [2] - The recognition of IRE under CPT Category I codes is expected to enhance billing precision for healthcare providers, leading to broader insurance coverage and defined reimbursement rates for NanoKnife procedures [3] Company Developments - The NanoKnife System, which utilizes IRE technology to ablate targeted cells without thermal energy, has shown solid growth and previously received FDA clearance for surgical ablation of soft tissue [4] - The system was also granted Breakthrough Device Designation by the FDA, highlighting its innovative approach in the medical field [4] - ANGO's market capitalization currently stands at $265.8 million, and the company reported an earnings surprise of 26.7% in the last quarter [2] Industry Prospects - The global pancreatic cancer treatment market was valued at $2.86 billion in 2023 and is projected to exceed $10.69 billion by 2032, with a compound annual growth rate (CAGR) of 15.8% [5] - Factors driving market growth include unhealthy lifestyles, alcohol consumption, and obesity, which are primary causes of pancreatic cancer [5]